POINT Biopharma Global Inc. Common Stock
PNT was delisted on the 26th of December, 2023.
106 hedge funds and large institutions have $470M invested in POINT Biopharma Global Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 40 increasing their positions, 21 reducing their positions, and 10 closing their positions.
220% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 10
90% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 21
42% more capital invested
Capital invested by funds: $330M → $470M (+$140M)
26% more funds holding
Funds holding: 84 → 106 (+22)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$38.3M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$23.9M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$18.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$14.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$61.3M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$5.8M |
| 3 |
PA
Perceptive Advisors
New York
|
-$4.87M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.95M |
| 5 |
RI
RTW Investments
New York
|
-$3.34M |
PNT Hedge Fund Activity: Q3 2022 in Review
106 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q3 2022, worth a combined $470M — up 42% from $330M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new PNT positions and 10 closed out — a net gain of 22 holders — while 40 added to existing stakes and 21 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $38.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $61.3M sold.
- 106 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q3 2022, up from 84 in Q2 2022.
- Funds reported $470M of POINT Biopharma Global Inc. Common Stock stock for Q3 2022, up 42% quarter-over-quarter.
- 32 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q3 2022 and 10 closed out, a net change of +22 holders.
- The largest POINT Biopharma Global Inc. Common Stock buyer in Q3 2022 was PFM Health Sciences, an estimated $38.3M added.
- The largest POINT Biopharma Global Inc. Common Stock seller in Q3 2022 was RA Capital Management, an estimated $61.3M sold.
Based on aggregated 13F filings for Q3 2022.